GRI Bio, Inc. (GRI) stock
Close on Nov 12, 2026Market cap $3.98MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.39
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.66M
- EPS, diluted
- -$121.80
- Free cash flow
- -$10.19M
- Book value per share
- $5.70
- Diluted shares
- 2M
Trading
- Previous close
- $1.83
- Open
- $1.73
- Day's range
- $1.72 – $1.88
- Volume
- 48,019
- Average volume (20 days)
- 47,841
- Beta (5 years)
- 0.76
- 52-week range
- $1.36 – $64.13
- RSI (14 days)
- 56.3
- Volatility (1 year)
- 129.2%
- Relative volume
- 0.19×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GRI | S&P 500 | Difference | GRI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.9% | -2.7% | +18.6 pts | ||
| 3 months | -6.7% | -1.7% | −4.9 pts | ||
| Year to date | -73.7% | +11.9% | −85.6 pts | ||
| 1 year | -96.5% | +12.0% | −108.5 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -96.8% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -95.1% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases GRI Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Results
- Results
- News
About GRI Bio
Pharmaceutical Preparations
GRI Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses. Its pipeline concentrates on inflammatory, fibrotic, and autoimmune disorders by regulating Natural Killer T (NKT) cell activity. The company's lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant NKT cells being developed to treat severe fibrotic lung diseases, primarily idiopathic pulmonary fibrosis. Its portfolio also includes GRI-0803, an oral activator of type 2 diverse NKT cells aimed at treating autoimmune conditions such as systemic lupus erythematosus, along with a proprietary compound library. Because its pipeline is in clinical and preclinical development stages, the company serves patient populations in clinical trials rather than commercial end customers.
Company profile, executives and historyGRI Bio stock: common questions
What is GRI Bio's stock price?
GRI closed at $1.82 on Nov 12, 2026, down 0.55% on the day. Over the past 52 weeks it traded between $1.36 and $64.13.
What is GRI Bio's market cap?
GRI Bio was worth $3.98M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GRI's P/E ratio?
GRI Bio lost money over fiscal 2025 (diluted EPS -$121.80), so it has no meaningful P/E ratio.
Does GRI Bio pay a dividend?
No. GRI Bio has not paid a cash dividend over the last twelve months.
How has GRI stock performed over the past year?
Including dividends, GRI returned -96.5% over the past year, against +12.0% for the S&P 500.
How many GRI shares are sold short?
0M shares were sold short at the latest FINRA report, 4.12% of the float, or 1.6 days of average trading volume.
Who are GRI Bio's competitors?
Companies most similar to GRI Bio by business, industry and size include CRVS, ACRS, ALMS, YARW, RCUS.
See a number that looks wrong?